Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

KYMR

Kymera Therapeutics Inc

Feb 13 • 04:00PM ET

82.34

-1.68 -2.00 %

Healthcare • Biotechnology • USA • NASD

Peers: SRRK NRIX ARDX QURE KPTI CRNC RVNC MREO ONCT

| Held by: VTI VB IWM XBI VBK VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-3.60	Insider Own	14.73%	Shs Outstand	71.74M	Perf Week	3.46%
Market Cap	6.50B	Forward P/E	-	EPS next Y	-3.64	Insider Trans	13.08%	Shs Float	67.32M	Perf Month	9.48%
Enterprise Value	6.08B	PEG	-	EPS next Q	-0.80	Inst Own	94.17%	Short Float	13.90%	Perf Quarter	29.61%
Income	-295.12M	P/S	148.65	EPS this Y	-17.76%	Inst Trans	6.31%	Short Ratio	9.51	Perf Half Y	98.17%
Sales	43.73M	P/B	6.24	EPS next Y	-3.61%	ROA	-27.62%	Short Interest	9.36M	Perf YTD	5.82%
Book/sh	13.19	P/C	12.86	EPS next 5Y	-9.11%	ROE	-32.09%	52W High	103.00 -20.06%	Perf Year	124.79%
Cash/sh	6.41	P/FCF	-	EPS past 3/5Y	-12.62% -26.36%	ROIC	-29.03%	52W Low	19.44 323.45%	Perf 3Y	149.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-13.54% 74.20%	Gross Margin	81.13%	Volatility	5.29% 5.02%	Perf 5Y	22.88%
Dividend TTM	-	EV/Sales	139.01	EPS Y/Y TTM	-54.47%	Oper. Margin	-750.91%	ATR (14)	3.92	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.38	Sales Y/Y TTM	-50.05%	Profit Margin	-674.81%	RSI (14)	61.74	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	7.38	EPS Q/Q	-14.68%	SMA20	9.40%	Beta	2.21	Target Price	116.71
Payout	-	Debt/Eq	0.09	Sales Q/Q	-26.12%	SMA50	6.23%	Rel Volume	0.60	Prev Close	84.02
Employees	188	LT Debt/Eq	0.07	Earnings	Nov 04 BMO	SMA200	48.98%	Avg Volume	983.55K	Price	82.34
IPO	Aug 21, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-22.13% -87.41%	Trades		Volume	589,252	Change	-2.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$133
Jan-06-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-03-25	Resumed	Guggenheim	Buy	$90
Oct-24-25	Reiterated	B. Riley Securities	Buy	$60 → $80
Oct-21-25	Initiated	Mizuho	Outperform	$81
Sep-18-25	Reiterated	H.C. Wainwright	Buy	$60 → $70
Sep-17-25	Initiated	Barclays	Overweight	$60
Sep-16-25	Initiated	RBC Capital Mkts	Outperform	$70
Jul-30-25	Resumed	B. Riley Securities	Buy	$60
Jul-03-25	Resumed	Morgan Stanley	Overweight	$70
Jun-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$79
Jun-03-25	Upgrade	B. Riley Securities	Neutral → Buy	$60
Jun-02-25	Upgrade	BofA Securities	Neutral → Buy	$51
May-20-25	Resumed	Stifel	Buy	$55
Mar-13-25	Initiated	Citigroup	Buy	$52
Dec-10-24	Initiated	BTIG Research	Buy	$60
Dec-06-24	Initiated	BMO Capital Markets	Market Perform	$55
Dec-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$57
Nov-18-24	Initiated	Stephens	Overweight	$65
Sep-09-24	Resumed	Leerink Partners	Outperform	$60

Show Previous Ratings

Feb-14-26 01:03AM	Kymera Therapeutics Touts Once-Daily Oral Biologics-Like KT-621 at Guggenheim Conference (MarketBeat)
Feb-04-26 07:00AM	Kymera Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire)
Jan-30-26 10:11AM	KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate (Zacks)
Jan-29-26 07:00AM	Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Jan-15-26 11:35AM	Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside (Insider Monkey) -5.44%
07:00AM	Loading…
Jan-13-26 07:00AM	Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs (GlobeNewswire)
Jan-12-26 12:00PM	Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why (Zacks)
Jan-06-26 07:00AM	Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 (GlobeNewswire)
Jan-05-26 01:45PM	KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? (Zacks)
Jan-01-26 11:35AM	Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks (MarketBeat)
Dec-30-25 08:45AM	The Biggest IPO of the Year Prompts Huge Insider Buy (24/7 Wall St.)
Dec-17-25 09:45AM	Share Offerings Prompt Huge Insider Buying in These 3 Biotechs (24/7 Wall St.)
Dec-14-25 03:30AM	Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. (Barrons.com)
Dec-12-25 10:30AM	Kymera's Eczema Drug Gets Fast Track Designation in the United States (Zacks)
Dec-11-25 04:01PM	Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Loading…
07:00AM	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis (GlobeNewswire)
Dec-09-25 11:30PM	Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering (GlobeNewswire) -7.87%
02:23PM	Kymera (KYMR) Jumps to All-Time High as Eczema Treatment Results Impress (Insider Monkey)
10:43AM	KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study (Zacks)
Dec-08-25 04:09PM	Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent? (Investor's Business Daily) +41.55%
04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
03:10PM	This Drugmaker's Stock Is Soaring Over 40% Monday (Investopedia)
01:07PM	Kymera Therapeutics Stock Heads for Record. Why Investors Are Excited About Its Anti-Inflammatory Drug. (Barrons.com)
07:42AM	Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug. (Barrons.com)
07:00AM	Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-05-25 04:01PM	Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 (GlobeNewswire)
11:30AM	Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? (Zacks)
Dec-04-25 11:30AM	Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-26-25 07:33AM	Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? (Zacks)
07:00AM	Loading…
Nov-25-25 07:00AM	Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Nov-24-25 07:00AM	Kymera Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-04-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-03-25 07:26AM	Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-28-25 07:00AM	Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-27-25 10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks)
07:00AM	Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting (GlobeNewswire)
Oct-23-25 10:00AM	Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-01-25 09:38AM	Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline (Zacks)
Sep-17-25 07:00AM	Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses (GlobeNewswire)
Sep-16-25 12:30PM	Kymera initiated at Outperform on potential of lead skin drug (Investing.com)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-07-25 10:08AM	Why Kymera (KYMR) Could Be One of Biotech's Most Interesting Growth Stories? (Insider Monkey)
Sep-03-25 07:00AM	Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary (GlobeNewswire) +6.41%
Aug-27-25 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-12-25 03:04AM	Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com) +5.81%
Aug-11-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -7.24%
07:00AM	Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-08-25 09:23AM	GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up (Zacks)
09:20AM	Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result (GuruFocus.com)
Aug-06-25 10:00AM	CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Aug-04-25 07:00AM	Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 (GlobeNewswire)
Jul-30-25 10:00AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-18-25 09:54AM	Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? (Zacks)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating (Insider Monkey)
Jul-09-25 06:02AM	Morgan Stanley Puts These 2 Stocks on Its Buy List Heres Why You Should Follow (TipRanks)
Jun-30-25 09:32AM	NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-28-25 04:16AM	Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer (Insider Monkey)
Jun-27-25 10:19AM	Kymeras partnerships with Sanofi and Gilead drive value (Investing.com)
Jun-26-25 11:56PM	Kymera Therapeutics Announces Pricing of $250 Million Public Offering (GlobeNewswire)
10:45AM	Kymera weakness a buying opportunity, says Stifel (TipRanks)
09:06AM	Morning Movers: General Mills dips following fourth quarter report (TipRanks)
08:40AM	KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update (Zacks)
Jun-25-25 04:05PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
01:04PM	Gilead eyes Kymeras adhesive cancer drug in $750m deal (Pharmaceutical Technology)
08:07AM	Kymera adds Gilead as research partner, while advancing new candidate with Sanofi (BioPharma Dive)
07:05AM	Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update (GlobeNewswire)
07:00AM	Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders (Business Wire)
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat)
Jun-06-25 03:13PM	Kymera Therapeutics Stock Earns 92 RS Rating (Investor's Business Daily)
Jun-05-25 04:16PM	Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial (Barrons.com) +7.68%
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
02:22AM	Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 10:29AM	Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response (Benzinga) +45.51%
07:44AM	Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster. (Barrons.com)
07:00AM	Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
May-30-25 04:01PM	Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 (GlobeNewswire)
May-29-25 07:00AM	Kymera Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire) +5.03%
May-19-25 12:15PM	Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference (GlobeNewswire)
May-10-25 07:00AM	Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
May-09-25 01:29PM	Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging (Zacks)
08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:01AM	Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases (GlobeNewswire)
07:00AM	Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
May-08-25 09:26AM	What To Expect From Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings (GuruFocus.com) +5.70%
May-07-25 07:00AM	Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference (GlobeNewswire)
Apr-25-25 06:03PM	Why Kymera Therapeutics Stock Crushed it This Week (Motley Fool)
Apr-24-25 07:00AM	Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025 (GlobeNewswire) +9.32%
Apr-22-25 07:00AM	Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader (GlobeNewswire) +6.04%
Apr-10-25 10:10AM	Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last? (Zacks) -6.47%
Apr-09-25 07:00AM	Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer (GlobeNewswire) +13.78%
Feb-28-25 02:15AM	Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com)
Feb-27-25 08:15AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -14.45%
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-26-25 07:33AM	What To Expect From Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings (GuruFocus.com)
07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-20-25 07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27 (GlobeNewswire)
Feb-19-25 09:15AM	NAYA Biosciences Announces Nomination of New Board Members (GlobeNewswire)

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Esposito Pamela	Director	Jan 20 '26	Option Exercise	39.34	5,500	216,350	5,500	Jan 20 06:30 PM
Esposito Pamela	Director	Jan 20 '26	Sale	67.91	5,500	373,521	0	Jan 20 06:30 PM
PAMELA ESPOSITO	Director	Jan 20 '26	Proposed Sale	69.54	5,500	382,470		Jan 20 04:29 PM
Mainolfi Nello	Chief Executive Officer	Jan 05 '26	Option Exercise	32.07	3,118	99,994	666,195	Jan 06 04:40 PM
Mainolfi Nello	Chief Executive Officer	Dec 31 '25	Option Exercise	2.08	30,000	62,400	693,077	Dec 31 05:23 PM
Mainolfi Nello	Chief Executive Officer	Dec 31 '25	Sale	78.06	30,000	2,341,939	663,077	Dec 31 05:23 PM
Mainolfi Nello	Officer	Dec 31 '25	Proposed Sale	77.69	30,000	2,330,700		Dec 31 04:06 PM
Mainolfi Nello	Chief Executive Officer	Dec 17 '25	Option Exercise	38.53	2,595	99,985	663,077	Dec 17 06:07 PM
Esposito Pamela	Director	Dec 17 '25	Option Exercise	37.82	27,563	1,042,483	27,563	Dec 17 06:07 PM
Esposito Pamela	Director	Dec 17 '25	Sale	82.16	27,563	2,264,480	0	Dec 17 06:07 PM
PAMELA ESPOSITO	Director	Dec 17 '25	Proposed Sale	84.19	27,563	2,320,529		Dec 17 04:23 PM
Booth Bruce	Director	Dec 10 '25	Sale	91.73	229,809	21,080,724	686,477	Dec 12 06:37 PM
Booth Bruce	Director	Dec 11 '25	Sale	91.23	6,101	556,594	685,501	Dec 12 06:37 PM
Booth Bruce	Director	Dec 12 '25	Sale	91.04	678	61,725	685,393	Dec 12 06:37 PM
Atlas Venture Opportunity Fund	Director	Dec 12 '25	Proposed Sale	89.68	108	9,685		Dec 12 05:20 PM
Atlas Venture Fund X, L.P.	Director	Dec 12 '25	Proposed Sale	89.68	570	51,118		Dec 12 05:08 PM
Atlas Venture Opportunity Fund	Director	Dec 11 '25	Proposed Sale	87.81	976	85,703		Dec 11 05:13 PM
Atlas Venture Fund X, L.P.	Director	Dec 11 '25	Proposed Sale	87.81	5,125	450,026		Dec 11 05:01 PM
BAKER BROS. ADVISORS LP	Director	Dec 11 '25	Buy	86.00	2,005,813	172,499,918	7,955,916	Dec 11 04:19 PM
Atlas Venture Opportunity Fund	Director	Dec 10 '25	Proposed Sale	89.89	36,769	3,305,165		Dec 10 06:39 PM
Atlas Venture Fund X, L.P.	Director	Dec 10 '25	Proposed Sale	89.89	193,040	17,352,366		Dec 10 06:31 PM
Albers Jeffrey W.	Director	Dec 08 '25	Option Exercise	14.18	5,000	70,900	5,000	Dec 08 06:09 PM
Albers Jeffrey W.	Director	Dec 08 '25	Sale	89.76	5,000	448,823	0	Dec 08 06:09 PM
Mainolfi Nello	Chief Executive Officer	Dec 08 '25	Option Exercise	2.08	100,000	208,000	760,482	Dec 08 06:09 PM
Mainolfi Nello	Chief Executive Officer	Dec 08 '25	Sale	89.17	100,000	8,917,000	660,482	Dec 08 06:09 PM
Gollob Jared	Chief Medical Officer	Dec 08 '25	Option Exercise	5.33	49,307	262,806	159,299	Dec 08 06:09 PM
Gollob Jared	Chief Medical Officer	Dec 08 '25	Sale	88.67	49,307	4,371,833	109,992	Dec 08 06:09 PM
Mainolfi Nello	Officer	Dec 08 '25	Proposed Sale	89.17	100,000	8,917,000		Dec 08 06:05 PM
Jared Gollob	Officer	Dec 08 '25	Proposed Sale	66.62	49,307	3,284,832		Dec 08 06:03 PM
JEFFREY ALBERS	Director	Dec 08 '25	Proposed Sale	66.62	5,000	333,100		Dec 08 06:03 PM
Mainolfi Nello	Chief Executive Officer	Oct 29 '25	Option Exercise	2.08	30,000	62,400	690,482	Oct 29 05:19 PM
Mainolfi Nello	Chief Executive Officer	Oct 29 '25	Sale	60.99	30,000	1,829,737	660,482	Oct 29 05:19 PM
Mainolfi Nello	Officer	Oct 29 '25	Proposed Sale	61.68	30,000	1,850,400		Oct 29 04:03 PM
Gollob Jared	Chief Medical Officer	Oct 15 '25	Option Exercise	1.64	51,209	84,185	169,568	Oct 15 05:28 PM
Gollob Jared	Chief Medical Officer	Oct 15 '25	Sale	61.42	59,576	3,659,254	109,992	Oct 15 05:28 PM
Jared Gollob	Officer	Oct 15 '25	Proposed Sale	58.26	59,576	3,470,898		Oct 15 04:36 PM
Gollob Jared	Chief Medical Officer	Oct 13 '25	Option Exercise	1.66	1,473	2,448	121,473	Oct 14 05:11 PM
Gollob Jared	Chief Medical Officer	Oct 13 '25	Sale	60.00	3,114	186,840	118,359	Oct 14 05:11 PM
Albers Jeffrey W.	Director	Oct 13 '25	Option Exercise	10.34	5,000	51,700	5,000	Oct 14 07:55 AM
Albers Jeffrey W.	Director	Oct 13 '25	Sale	59.19	5,000	295,949	0	Oct 14 07:55 AM
Jared Gollob	Officer	Oct 13 '25	Proposed Sale	57.21	3,114	178,152		Oct 14 07:43 AM
JEFFREY ALBERS	Director	Oct 13 '25	Proposed Sale	57.21	5,000	286,050		Oct 14 07:42 AM
Jacobs Bruce N.	Chief Financial Officer	Sep 17 '25	Option Exercise	2.08	79,220	164,778	306,629	Sep 17 05:16 PM
Jacobs Bruce N.	Chief Financial Officer	Sep 17 '25	Sale	50.00	79,220	3,961,380	227,409	Sep 17 05:16 PM
BRUCE N. JACOBS	Officer	Sep 17 '25	Proposed Sale	48.78	79,220	3,864,352		Sep 17 04:24 PM
Mainolfi Nello	Chief Executive Officer	Sep 16 '25	Option Exercise	2.08	30,000	62,400	690,482	Sep 16 04:11 PM
Mainolfi Nello	Chief Executive Officer	Sep 16 '25	Sale	49.00	30,000	1,470,000	660,482	Sep 16 04:11 PM
Mainolfi Nello	Officer	Sep 16 '25	Proposed Sale	49.00	30,000	1,470,000		Sep 16 04:05 PM
BVF PARTNERS L P/IL	Director	Jun 30 '25	Buy	44.00	317,167	13,955,348	2,798,795	Jul 01 06:41 PM
BAKER BROS. ADVISORS LP	Director	Jun 30 '25	Buy	44.00	655,500	28,842,000	6,117,295	Jun 30 08:15 PM
Ridloff Elena	Director	Jun 11 '25	Option Exercise	20.29	4,500	91,305	4,500	Jun 11 04:47 PM
Ridloff Elena	Director	Jun 11 '25	Sale	50.00	4,500	225,000	0	Jun 11 04:47 PM
ELENA RIDLOFF	Director	Jun 11 '25	Proposed Sale	48.60	4,500	218,700		Jun 11 04:26 PM
Esposito Pamela	Director	Jun 03 '25	Option Exercise	29.55	5,000	147,750	5,000	Jun 03 06:30 PM
Esposito Pamela	Director	Jun 03 '25	Sale	49.04	5,000	245,186	0	Jun 03 06:30 PM
Ridloff Elena	Director	Jun 03 '25	Option Exercise	27.67	12,000	332,040	12,000	Jun 03 06:30 PM
Ridloff Elena	Director	Jun 03 '25	Sale	46.10	12,000	553,200	0	Jun 03 06:30 PM
Mainolfi Nello	Chief Executive Officer	Jun 03 '25	Option Exercise	2.08	30,000	62,400	690,482	Jun 03 06:30 PM
Mainolfi Nello	Chief Executive Officer	Jun 03 '25	Sale	49.00	30,000	1,470,000	660,482	Jun 03 06:30 PM
Albers Jeffrey W.	Director	Jun 03 '25	Option Exercise	10.34	6,349	65,649	6,349	Jun 03 06:30 PM
Albers Jeffrey W.	Director	Jun 03 '25	Sale	49.00	6,349	311,101	0	Jun 03 06:30 PM
Mainolfi Nello	Officer	Jun 03 '25	Proposed Sale	49.00	30,000	1,470,000		Jun 03 04:31 PM
JEFFREY ALBERS	Director	Jun 03 '25	Proposed Sale	43.13	6,349	273,832		Jun 03 04:25 PM
PAMELA ESPOSITO	Director	Jun 03 '25	Proposed Sale	43.13	5,000	215,650		Jun 03 04:25 PM
ELENA RIDLOFF	Director	Jun 03 '25	Proposed Sale	43.13	12,000	517,560		Jun 03 04:24 PM
Chadwick Jeremy G	Chief Operating Officer	May 23 '25	Sale	29.30	2,575	75,436	66,420	May 23 04:30 PM
Chadwick Jeremy G	Officer	May 23 '25	Proposed Sale	30.17	2,575	77,688		May 23 04:20 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 31 '25	Option Exercise	2.08	25,000	52,000	226,886	Apr 01 08:00 AM
Chiniara Ellen	Chief Legal Officer	Mar 03 '25	Sale	30.45	2,241	68,239	80,085	Mar 03 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 03 '25	Sale	30.45	1,383	42,113	67,800	Mar 03 06:30 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 03 '25	Sale	30.45	7,035	214,219	201,886	Mar 03 06:30 PM
Gollob Jared	Chief Medical Officer	Mar 03 '25	Sale	30.45	5,740	174,786	120,000	Mar 03 06:30 PM
Gollob Jared	Officer	Mar 03 '25	Proposed Sale	31.35	5,740	179,949		Mar 03 06:00 PM
Chiniara Ellen	Officer	Mar 03 '25	Proposed Sale	31.35	2,241	70,255		Mar 03 06:00 PM
Chadwick Jeremy G	Officer	Mar 03 '25	Proposed Sale	31.35	1,383	43,357		Mar 03 06:00 PM
Jacobs Bruce N.	Officer	Mar 03 '25	Proposed Sale	31.35	7,035	220,547		Mar 03 06:00 PM

Open in Screener

IRON

Disc Medicine Inc

Feb 13 • 04:00PM ET

55.95

-15.70 -21.91 %

Healthcare • Biotechnology • USA • NASD

IRON Disc Medicine Inc daily Stock Chart

Peers: VRTX ALNY CRSP BEAM EDIT NTLA SRPT IONS BLUE SGMO

| Held by: VTI XBI IWM VXF IWO IBB SCHA VTWO VHT ITOT

Index	RUT	P/E	-	EPS (ttm)	-5.36	Insider Own	27.99%	Shs Outstand	35.01M	Perf Week	-29.82%
Market Cap	2.11B	Forward P/E	-	EPS next Y	-7.02	Insider Trans	-10.48%	Shs Float	27.18M	Perf Month	-27.41%
Enterprise Value	1.53B	PEG	-	EPS next Q	-1.75	Inst Own	83.32%	Short Float	15.09%	Perf Quarter	-34.96%
Income	-181.11M	P/S	-	EPS this Y	-55.49%	Inst Trans	3.85%	Short Ratio	7.13	Perf Half Y	-7.86%
Sales	0.00M	P/B	3.42	EPS next Y	-13.95%	ROA	-32.18%	Short Interest	4.10M	Perf YTD	-29.54%
Book/sh	16.38	P/C	3.43	EPS next 5Y	-15.53%	ROE	-34.78%	52W High	99.50 -43.77%	Perf Year	3.42%
Cash/sh	16.32	P/FCF	-	EPS past 3/5Y	54.09% 38.12%	ROIC	-30.00%	52W Low	30.82 81.54%	Perf 3Y	131.39%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	22.11% 9.45%	Perf 5Y	-55.45%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-34.96%	Oper. Margin	-	ATR (14)	6.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	23.45	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	25.21	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	23.45	EPS Q/Q	-99.39%	SMA20	-26.28%	Beta	0.86	Target Price	111.42
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	-30.61%	Rel Volume	8.68	Prev Close	71.65
Employees	84	LT Debt/Eq	0.05	Earnings	Nov 06 BMO	SMA200	-17.55%	Avg Volume	574.94K	Price	55.95
IPO	Aug 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-22.74% -	Trades		Volume	4,989,722	Change	-21.91%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-03-25	Resumed	Stifel	Buy	$125
Jul-21-25	Initiated	Truist	Buy	$86
Jul-03-25	Resumed	Morgan Stanley	Overweight	$85
Jun-11-25	Resumed	Raymond James	Strong Buy	$89
Feb-27-25	Initiated	TD Cowen	Buy
Nov-05-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$85
Nov-04-24	Upgrade	Raymond James	Outperform → Strong Buy	$66 → $110
Oct-23-24	Initiated	Jefferies	Buy	$89
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-22-24	Initiated	Wells Fargo	Overweight	$75
Apr-01-24	Downgrade	Raymond James	Strong Buy → Outperform	$40
Dec-19-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $65
Jun-09-23	Upgrade	Raymond James	Outperform → Strong Buy	$50 → $75
Jun-07-23	Initiated	H.C. Wainwright	Buy	$55
May-17-23	Initiated	Raymond James	Outperform	$50
Apr-28-23	Initiated	Cantor Fitzgerald	Overweight	$45
Apr-21-23	Initiated	Stifel	Buy	$37
Apr-20-23	Initiated	Morgan Stanley	Overweight	$37
Mar-23-23	Initiated	BMO Capital Markets	Outperform	$40
Feb-28-23	Initiated	SVB Securities	Outperform	$36

Show Previous Ratings

Feb-13-26 03:04PM	Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP (GlobeNewswire) -21.91%
Jan-28-26 09:55AM	Wall Street Analysts Believe Disc Medicine, Inc. (IRON) Could Rally 48.62%: Here's is How to Trade (Zacks)
Jan-16-26 01:34PM	Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action (Benzinga)
Jan-15-26 02:09PM	State Street's crypto push, FDA delays review of Eli Lilly GLP-1 (Yahoo Finance Video) -7.84%
08:26AM	FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (Benzinga)
04:59PM	Loading…
Jan-13-26 04:59PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Jan-12-26 04:30PM	Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer (GlobeNewswire)
08:30AM	Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 (GlobeNewswire)
Jan-07-26 08:30AM	Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-25 05:14PM	Seadrill, Vestis, Mastercraft Boat, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-11-25 07:44AM	Leering Partners Lifts Disc Medicine, Inc. (IRON) Following EPP Drug NDA Application (Insider Monkey)
Dec-09-25 12:20AM	This is Why Disc Medicine, Inc. (IRON) is a Buy on Wall Street (Insider Monkey)
Dec-06-25 08:00AM	Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-06-25 08:30AM	Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-25 09:00AM	Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
08:30AM	Loading…
Oct-31-25 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-27-25 12:00PM	What Makes Disc Medicine, Inc. (IRON) a Strong Momentum Stock: Buy Now? (Zacks)
Oct-22-25 09:55AM	Does Disc Medicine, Inc. (IRON) Have the Potential to Rally 26.29% as Wall Street Analysts Expect? (Zacks)
Oct-21-25 12:14AM	Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Oct-20-25 08:25AM	FDA Grants First CNPV Vouchers, Igniting Rally in Biotech Stocks (GuruFocus.com)
07:00AM	Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
06:30AM	Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones (GlobeNewswire)
Oct-17-25 10:17AM	The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. (Investor's Business Daily) +20.95%
09:00AM	Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week (GlobeNewswire)
Oct-16-25 05:35PM	Disc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Sep-30-25 08:30AM	Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Aug-27-25 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-22-25 05:16PM	Rapid7, Residio Tech, and 4 More Stocks See Action From Activist Investors (Barrons.com)
Aug-07-25 08:30AM	Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-25 10:05AM	Disc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025 (Insider Monkey)
09:15AM	Loading…
Jul-22-25 09:15AM	OrbiMed Promotes Mona Ashiya to General Partner (PR Newswire)
Jul-21-25 08:00AM	Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025 (GlobeNewswire)
Jul-14-25 08:30AM	Disc Medicine Appoints Nadim Ahmed to its Board of Directors (GlobeNewswire)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT (Insider Monkey)
Jun-24-25 05:42PM	Leerink Partners Reiterates a Buy Rating on Disc Medicine (IRON) With an $85 Price Target (Insider Monkey) +6.42%
Jun-15-25 05:42AM	Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating (Insider Monkey)
Jun-12-25 07:30AM	Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress (GlobeNewswire)
Jun-11-25 09:45AM	Raymond James bullish on biotech firms on favorable valuation (Investing.com)
May-28-25 04:01PM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 09:30AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
May-13-25 08:00AM	Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-07-25 08:00AM	Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-25 08:00AM	Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF) (GlobeNewswire)
Apr-09-25 07:13AM	Disc Medicine: Forging Ahead In Hematology (Seeking Alpha) +12.89%
Mar-26-25 09:39PM	Is Disc Medicine, Inc. (NASDAQ:IRON) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
Mar-21-25 06:35PM	Victorias Secret, Bitdeer, and More Stocks See Activist Action (Barrons.com)
Mar-14-25 12:00PM	All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy (Zacks)
Mar-03-25 09:55AM	Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know (Zacks)
Feb-27-25 08:00AM	Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-25 08:00AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-12-25 09:55AM	Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-23-25 08:28AM	Disc raises $225.5m as it eyes approval of rare skin disorder drug (Pharmaceutical Technology)
Jan-22-25 09:35PM	Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-21-25 04:01PM	Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
07:45AM	Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission (GlobeNewswire)
Jan-20-25 07:00PM	Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Jan-17-25 04:00PM	Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-10-25 09:00AM	Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025 (GlobeNewswire) -5.27%
Dec-09-24 12:00PM	Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-08-24 08:00PM	Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-24-24 06:10AM	Raymond James Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Nov-13-24 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 08:00AM	Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 10:38AM	Disc Medicine secures $200m financing to support trials (Clinical Trials Arena)
Nov-08-24 08:30AM	Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. (GlobeNewswire)
Nov-05-24 09:00AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +11.20%
Nov-04-24 01:44PM	Disc teases potential NDA for rare skin disorder drug (Pharmaceutical Technology) +23.59%
07:50AM	Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval (GlobeNewswire)
Nov-01-24 04:01PM	Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire) +5.15%
Oct-25-24 01:00PM	Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week (GlobeNewswire)
Oct-23-24 08:00AM	Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer (GlobeNewswire) -7.72%
Oct-11-24 08:00AM	Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week (GlobeNewswire)
Sep-19-24 08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffe, MD as Chief Regulatory Officer (GlobeNewswire)
08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caff , MD as Chief Regulatory Officer (GlobeNewswire)
Aug-30-24 08:00AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 08:00AM	Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jun-28-24 08:11PM	Bitfarms Technologies, Vestis, and More Stocks See Action From Activist Investors (Barrons.com)
Jun-14-24 08:03AM	Disc Medicine Announces Underwritten Offering of Common Stock (GlobeNewswire) +18.16%
07:30AM	Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire)
May-30-24 09:00AM	Disc Medicine to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 10:30AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire)
May-13-24 08:00AM	Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
May-11-24 05:31AM	Disc Medicine Inc (IRON) Reports Q1 2024 Earnings: A Detailed Financial Overview (GuruFocus.com)
May-09-24 01:54PM	IRON Stock Earnings: Disc Medicine Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-02-24 02:24PM	Disc Medicine (IRON) Down on Mixed Results From AURORA Study (Zacks) -6.36%
Apr-01-24 04:19PM	Disc Medicine Plummets After Placebo Effect Confounds Sunlight Sensitivity Study (Investor's Business Daily) -45.05%
08:00AM	Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Mar-23-24 05:31AM	Disc Medicine Inc (IRON) Reports Earnings: A Detailed Look at Fiscal Performance (GuruFocus.com)
Mar-21-24 08:00AM	Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.52%
Mar-06-24 04:30PM	Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire) -5.18%
Feb-26-24 08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer (GlobeNewswire)
Feb-20-24 08:30AM	Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease (GlobeNewswire)
Feb-09-24 09:00AM	Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera (GlobeNewswire)
Feb-07-24 08:00AM	Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer (GlobeNewswire)
Jan-03-24 05:00PM	Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 06:35PM	Peabody Energy, Janus International, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-20-23 04:30PM	Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board (GlobeNewswire)
Dec-15-23 03:01PM	Insider Sell Alert: Director William White Sells 33,511 Shares of Disc Medicine Inc (IRON) (GuruFocus.com)
Dec-11-23 08:30PM	Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Khara Rahul	Chief Legal Officer	Jan 20 '26	Option Exercise	13.50	1,000	13,500	38,793	Jan 21 06:55 PM
Khara Rahul	Chief Legal Officer	Jan 20 '26	Sale	69.74	1,000	69,740	37,793	Jan 21 06:55 PM
Khara Rahul	Chief Legal Officer	Jan 02 '26	Option Exercise	13.50	6,500	87,750	44,293	Jan 05 08:02 PM
Khara Rahul	Chief Legal Officer	Jan 02 '26	Sale	78.69	6,500	511,472	37,793	Jan 05 08:02 PM
RAHUL KHARA	Officer	Jan 02 '26	Proposed Sale	79.41	7,500	595,575		Jan 02 04:30 PM
Savage William Jacob	Chief Medical Officer	Dec 22 '25	Option Exercise	9.97	3,143	31,350	78,845	Dec 29 08:50 PM
Quisel John D	Chief Executive Officer	Dec 19 '25	Option Exercise	1.01	12,300	12,423	184,128	Dec 19 06:16 PM
Bitterman Kevin	Director	Dec 17 '25	Sale	91.47	754	68,968	14,013	Dec 18 06:14 PM
AI DMI LLC	Affiliate	Dec 17 '25	Proposed Sale	87.49	50	4,374		Dec 17 07:48 PM
Atlas Venture Fund XII, LP	Shareholder	Dec 17 '25	Proposed Sale	91.47	148	13,538		Dec 17 05:08 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 17 '25	Proposed Sale	91.47	213	19,483		Dec 17 05:07 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 17 '25	Proposed Sale	91.47	393	35,948		Dec 17 05:06 PM
Atlas Venture Fund X, LP	Shareholder	Dec 17 '25	Proposed Sale	91.47	818	74,822		Dec 17 05:05 PM
Bitterman Kevin	Director	Dec 15 '25	Option Exercise	13.50	7,000	94,500	7,000	Dec 16 09:43 PM
Bitterman Kevin	Director	Dec 16 '25	Sale	91.24	68,923	6,288,535	14,161	Dec 16 09:43 PM
Bitterman Kevin	Director	Dec 15 '25	Sale	91.28	62,693	5,722,608	28,520	Dec 16 09:43 PM
Bitterman Kevin	Director	Dec 12 '25	Sale	92.39	45,507	4,204,407	41,519	Dec 16 09:43 PM
Bitterman Kevin	Director	Dec 15 '25	Sale	91.87	7,000	643,090	0	Dec 16 09:43 PM
Savage William Jacob	Chief Medical Officer	Dec 15 '25	Sale	91.22	13,093	1,194,372	75,702	Dec 16 09:31 PM
AI DMI LLC	Affiliate	Dec 16 '25	Proposed Sale	91.47	39,769	3,637,670		Dec 16 06:27 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 16 '25	Proposed Sale	92.00	10,898	1,002,616		Dec 16 05:18 PM
Atlas Venture Fund XII, LP	Shareholder	Dec 16 '25	Proposed Sale	92.00	4,359	401,028		Dec 16 05:18 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 16 '25	Proposed Sale	92.00	5,666	521,272		Dec 16 05:17 PM
Atlas Venture Fund X, LP	Shareholder	Dec 16 '25	Proposed Sale	92.00	22,666	2,085,272		Dec 16 05:16 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 16 '25	Proposed Sale	91.47	25,000	2,286,750		Dec 16 05:15 PM
Atlas Venture Fund X, L.P.	Shareholder	Dec 16 '25	Proposed Sale	91.47	52,000	4,756,440		Dec 16 05:03 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 16 '25	Proposed Sale	91.47	13,000	1,189,110		Dec 16 04:59 PM
Atlas Venture Associates XII,	Shareholder	Dec 16 '25	Proposed Sale	91.47	10,000	914,700		Dec 16 04:56 PM
AI DMI LLC	Affiliate	Dec 15 '25	Proposed Sale	92.00	5,843	537,556		Dec 15 07:52 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 15 '25	Proposed Sale	92.00	8,851	814,292		Dec 15 06:56 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 15 '25	Proposed Sale	92.00	17,433	1,603,836		Dec 15 06:56 PM
Atlas Venture Fund X, L.P.	Shareholder	Dec 15 '25	Proposed Sale	92.00	36,877	3,392,684		Dec 15 06:50 PM
Atlas Venture Associates XII,	Shareholder	Dec 15 '25	Proposed Sale	92.00	6,839	629,188		Dec 15 06:44 PM
Quisel John D	Chief Executive Officer	Dec 11 '25	Option Exercise	9.86	40,000	394,400	211,828	Dec 15 05:49 PM
Quisel John D	Chief Executive Officer	Dec 11 '25	Sale	93.05	40,000	3,721,931	171,828	Dec 15 05:49 PM
KEVIN J BITTERMAN	Officer	Dec 15 '25	Proposed Sale	91.87	7,000	643,061		Dec 15 05:45 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 15 '25	Proposed Sale	91.85	8,009	735,627		Dec 15 05:40 PM
Atlas Venture Fund XII, LP	Shareholder	Dec 15 '25	Proposed Sale	91.85	6,160	565,796		Dec 15 05:37 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 15 '25	Proposed Sale	91.85	15,401	1,414,582		Dec 15 05:35 PM
Atlas Venture Fund X, LP	Shareholder	Dec 15 '25	Proposed Sale	91.85	32,035	2,942,415		Dec 15 05:34 PM
WILLIAM SAVAGE	Officer	Dec 15 '25	Proposed Sale	91.85	13,093	1,202,592		Dec 15 04:14 PM
AI DMI LLC	Affiliate	Dec 12 '25	Proposed Sale	91.85	29,388	2,699,288		Dec 12 09:50 PM
Atlas Venture Fund XII, LP	Shareholder	Dec 12 '25	Proposed Sale	93.60	9,481	887,422		Dec 12 05:15 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 12 '25	Proposed Sale	93.60	12,325	1,153,620		Dec 12 05:13 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 12 '25	Proposed Sale	93.60	23,701	2,218,414		Dec 12 05:11 PM
Atlas Venture Fund X, LP	Shareholder	Dec 12 '25	Proposed Sale	93.60	49,299	4,614,386		Dec 12 05:10 PM
JOHN QUISEL	Director	Dec 11 '25	Proposed Sale	92.85	40,000	3,714,000		Dec 11 04:25 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Nov 11 '25	Option Exercise	2.65	30,000	79,500	70,555	Nov 13 08:22 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Nov 11 '25	Sale	84.70	30,000	2,540,923	40,555	Nov 13 08:22 PM
JONATHAN YU	Officer	Nov 11 '25	Proposed Sale	83.58	30,000	2,507,400		Nov 12 06:56 AM
AI DMI LLC	10% Owner	Oct 22 '25	Sale	80.47	744,047	59,873,462	2,814,379	Oct 24 04:01 PM
OrbiMed Private Investments VI	Shareholder	Oct 20 '25	Proposed Sale	89.94	482,308	43,378,782		Oct 20 08:54 PM
OrbiMed Genesis Master Fund, L	Shareholder	Oct 20 '25	Proposed Sale	89.94	186,541	16,777,498		Oct 20 08:52 PM
OrbiMed Private Investments VI	Shareholder	Oct 20 '25	Proposed Sale	89.94	746,171	67,110,620		Oct 20 08:47 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 17 '25	Proposed Sale	89.94	35,000	3,147,900		Oct 17 05:26 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 17 '25	Proposed Sale	89.94	35,000	3,147,900		Oct 17 05:23 PM
Atlas Venture Fund X, LP	Shareholder	Oct 17 '25	Proposed Sale	74.36	50,000	3,718,000		Oct 17 04:42 PM
Bitterman Kevin	Director	Oct 17 '25	Sale	88.91	70,000	6,223,934	385,549	Oct 17 04:41 PM
Bitterman Kevin	Director	Oct 15 '25	Sale	77.23	22,160	1,711,436	478,461	Oct 17 04:41 PM
Bitterman Kevin	Director	Oct 16 '25	Sale	77.11	1,425	109,882	477,036	Oct 17 04:41 PM
Atlas Venture Fund X, LP	Shareholder	Oct 16 '25	Proposed Sale	76.98	1,425	109,696		Oct 16 04:46 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 16 '25	Proposed Sale	76.98	1,425	109,696		Oct 16 04:46 PM
Atlas Venture Fund X, LP	Shareholder	Oct 15 '25	Proposed Sale	73.00	22,160	1,617,680		Oct 15 05:00 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 15 '25	Proposed Sale	73.00	22,160	1,617,680		Oct 15 05:00 PM
Bitterman Kevin	Director	Oct 08 '25	Sale	70.58	71,961	5,079,007	500,621	Oct 09 04:07 PM
Bitterman Kevin	Director	Oct 07 '25	Sale	68.38	18,039	1,233,493	572,582	Oct 09 04:07 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 08 '25	Proposed Sale	67.89	71,961	4,885,432		Oct 08 04:55 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 07 '25	Proposed Sale	69.28	18,039	1,249,742		Oct 07 05:16 PM
Quisel John D	Chief Executive Officer	Sep 09 '25	Option Exercise	1.01	10,000	10,100	171,828	Sep 11 06:00 PM
Bitterman Kevin	Director	Aug 22 '25	Sale	61.03	2,287	139,576	590,621	Aug 26 06:01 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 22 '25	Proposed Sale	59.75	2,287	136,648		Aug 22 04:29 PM
Atlas Venture Fund X, L.P.	Shareholder	Aug 22 '25	Proposed Sale	59.75	4,080	243,780		Aug 22 04:25 PM
Bitterman Kevin	Director	Aug 13 '25	Sale	61.15	24,962	1,526,426	600,120	Aug 15 07:23 PM
Bitterman Kevin	Director	Aug 14 '25	Sale	60.99	7,212	439,860	592,908	Aug 15 07:23 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 14 '25	Proposed Sale	61.10	7,212	440,653		Aug 14 04:24 PM
Atlas Venture Fund X, L.P.	Shareholder	Aug 14 '25	Proposed Sale	61.10	12,862	785,868		Aug 14 04:16 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 13 '25	Proposed Sale	59.03	24,962	1,473,507		Aug 13 04:26 PM
Atlas Venture Fund X, L.P.	Shareholder	Aug 13 '25	Proposed Sale	59.03	44,520	2,628,016		Aug 13 04:24 PM
Bitterman Kevin	Director	Aug 05 '25	Sale	60.95	395	24,075	625,082	Aug 07 05:00 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 05 '25	Proposed Sale	59.79	395	23,617		Aug 05 04:31 PM
Atlas Venture Fund X, L.P.	Shareholder	Aug 05 '25	Proposed Sale	59.79	705	42,152		Aug 05 04:24 PM
Bitterman Kevin	Director	Jul 30 '25	Sale	61.04	8,492	518,352	625,477	Aug 01 04:32 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 30 '25	Proposed Sale	59.80	8,492	507,822		Jul 30 04:18 PM
Atlas Venture Fund X, L.P.	Shareholder	Jul 30 '25	Proposed Sale	59.80	15,146	905,731		Jul 30 04:14 PM
Bitterman Kevin	Director	Jul 23 '25	Sale	60.97	29,837	1,819,162	647,002	Jul 25 05:22 PM
Bitterman Kevin	Director	Jul 24 '25	Sale	61.17	13,033	797,229	633,969	Jul 25 05:22 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 24 '25	Proposed Sale	60.94	13,033	794,231		Jul 24 04:27 PM
Atlas Venture Fund X, L.P.	Shareholder	Jul 24 '25	Proposed Sale	60.94	23,245	1,416,550		Jul 24 04:25 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 23 '25	Proposed Sale	60.74	29,837	1,812,299		Jul 23 04:30 PM
Atlas Venture Fund X, L.P.	Shareholder	Jul 23 '25	Proposed Sale	60.74	53,215	3,232,279		Jul 23 04:25 PM
Bitterman Kevin	Director	Jul 18 '25	Sale	61.13	664	40,590	676,839	Jul 22 04:44 PM
Franchi Jean M.	Chief Financial Officer	Jul 17 '25	Sale	59.00	2,031	119,829	63,499	Jul 18 04:51 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 18 '25	Proposed Sale	57.79	664	38,373		Jul 18 04:33 PM
Atlas Venture Fund X, L.P.	Shareholder	Jul 18 '25	Proposed Sale	57.79	1,184	68,423		Jul 18 04:31 PM
JEAN FRANCHI	Officer	Jul 17 '25	Proposed Sale	57.34	2,031	116,458		Jul 17 04:20 PM
Franchi Jean M.	Chief Financial Officer	Jul 10 '25	Sale	57.50	2,000	115,000	65,530	Jul 14 09:36 PM
Quisel John D	Chief Executive Officer	Jul 09 '25	Option Exercise	9.86	34,800	343,128	196,628	Jul 11 04:48 PM
Quisel John D	Chief Executive Officer	Jul 09 '25	Sale	55.33	34,800	1,925,525	161,828	Jul 11 04:48 PM
JEAN FRANCHI	Officer	Jul 10 '25	Proposed Sale	55.86	2,000	111,720		Jul 10 04:34 PM
JOHN QUISEL	Director	Jul 09 '25	Proposed Sale	52.97	34,800	1,843,356		Jul 09 04:17 PM

KYMR

Kymera Therapeutics Inc

IRON

Disc Medicine Inc

Upgrade your FINVIZ experience